BRPI0914091A2 - "igg variante, composição farmacêutica, kit, método para tratar em tumor, método para inibir atividade de vegf, método para modular permeabilidade vascular e método para inibir ou evitar crescimento de células de câncer" - Google Patents

"igg variante, composição farmacêutica, kit, método para tratar em tumor, método para inibir atividade de vegf, método para modular permeabilidade vascular e método para inibir ou evitar crescimento de células de câncer"

Info

Publication number: BRPI0914091A2
Authority: BR; Brazil
Prior art keywords: inhibiting; kit; pharmaceutical composition; cancer cell; cell growth
Prior art date: 2008-10-14

Application number

BRPI0914091A

Other languages

English (en)

Inventor

Henry B Lowman

Lisa A Damico

Napoleone Ferrara

Yik Andy Yeung

Yu-Ju G Meng

Original Assignee

Genentech Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-10-14

Filing date

2009-10-13

Publication date

2016-09-27

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41571534&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0914091(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-10-13 Application filed by Genentech Inc filed Critical Genentech Inc

2016-09-27 Publication of BRPI0914091A2 publication Critical patent/BRPI0914091A2/pt

2022-05-10 Publication of BRPI0914091B1 publication Critical patent/BRPI0914091B1/pt

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Oncology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

BRPI0914091-3A 2008-10-14 2009-10-13 Igg variante, composição farmacêutica, kit e usos de um igg variante BRPI0914091B1 (pt)

Applications Claiming Priority (9)

Application Number	Priority Date	Filing Date	Title
US10508608P	2008-10-14	2008-10-14
US61/105,086		2008-10-14
US15213109P	2009-02-12	2009-02-12
US61/152,131		2009-02-12
US17176809P	2009-04-22	2009-04-22
US61/171,768		2009-04-22
US22051409P	2009-06-25	2009-06-25
US61/220,514		2009-06-25
PCT/US2009/060443 WO2010045193A1 (en)	2008-10-14	2009-10-13	Immunoglobulin variants and uses thereof

Publications (2)

Publication Number	Publication Date
BRPI0914091A2 true BRPI0914091A2 (pt)	2016-09-27
BRPI0914091B1 BRPI0914091B1 (pt)	2022-05-10

Family

ID=41571534

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0914091-3A BRPI0914091B1 (pt)	2008-10-14	2009-10-13	Igg variante, composição farmacêutica, kit e usos de um igg variante

Country Status (21)

Country	Link
US (3)	US20100098730A1 (pt)
EP (2)	EP3524620A1 (pt)
JP (2)	JP5913980B2 (pt)
KR (3)	KR101834999B1 (pt)
CN (3)	CN102245208B (pt)
AR (1)	AR073829A1 (pt)
AU (1)	AU2009303526B2 (pt)
BR (1)	BRPI0914091B1 (pt)
CA (1)	CA2739429C (pt)
CL (1)	CL2015000148A1 (pt)
ES (1)	ES2828721T3 (pt)
IL (2)	IL212048B (pt)
MX (1)	MX2011004001A (pt)
PE (2)	PE20110707A1 (pt)
PH (1)	PH12016500081B1 (pt)
PL (1)	PL2352521T3 (pt)
RU (1)	RU2536937C2 (pt)
SG (2)	SG10201605250SA (pt)
TW (2)	TWI572359B (pt)
WO (1)	WO2010045193A1 (pt)
ZA (1)	ZA201102413B (pt)

Families Citing this family (115)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7183387B1 (en)	1999-01-15	2007-02-27	Genentech, Inc.	Polypeptide variants with altered effector function
CA2463879C (en) *	2001-10-25	2012-12-04	Genentech, Inc.	Glycoprotein compositions
EP2332985A3 (en)	2004-11-12	2012-01-25	Xencor, Inc.	Fc variants with altered binding to FcRn
CA2647846C (en)	2006-03-31	2016-06-21	Chugai Seiyaku Kabushiki Kaisha	Methods for controlling blood pharmacokinetics of antibodies
US20080127996A1 (en) *	2006-12-04	2008-06-05	Weinhold Dennis G	Method and apparatus to remediate an acid and/or liquid spill
RU2510400C9 (ru)	2007-09-26	2014-07-20	Чугаи Сейяку Кабусики Кайся	Способ модификации изоэлектрической точки антитела с помощью аминокислотных замен в cdr
SG193868A1 (en)	2007-09-26	2013-10-30	Chugai Pharmaceutical Co Ltd	Modified antibody constant region
US12492253B1 (en)	2008-02-25	2025-12-09	Xencor, Inc.	Anti-human C5 antibodies
TW201920257A (zh)	2008-04-11	2019-06-01	日商中外製藥股份有限公司	重複結合複數個抗原的抗原結合分子
TWI440469B (zh)	2008-09-26	2014-06-11	Chugai Pharmaceutical Co Ltd	Improved antibody molecules
EP2233500A1 (en) *	2009-03-20	2010-09-29	LFB Biotechnologies	Optimized Fc variants
SG175077A1 (en)	2009-04-07	2011-11-28	Roche Glycart Ag	Trivalent, bispecific antibodies
US9676845B2 (en)	2009-06-16	2017-06-13	Hoffmann-La Roche, Inc.	Bispecific antigen binding proteins
SG10201408401RA (en)	2009-09-16	2015-01-29	Genentech Inc	Coiled coil and/or tether containing protein complexes and uses thereof
TW201130971A (en)	2009-12-23	2011-09-16	Genentech Inc	Anti-Bv8 antibodies and uses thereof
AR080793A1 (es)	2010-03-26	2012-05-09	Roche Glycart Ag	Anticuerpos biespecificos
TWI667346B (zh) *	2010-03-30	2019-08-01	中外製藥股份有限公司	促進抗原消失之具有經修飾的FcRn親和力之抗體
MX346731B (es)	2010-04-23	2017-03-30	Genentech Inc *	Producción de proteínas heteromultiméricas.
WO2012025530A1 (en)	2010-08-24	2012-03-01	F. Hoffmann-La Roche Ag	Bispecific antibodies comprising a disulfide stabilized - fv fragment
SG10201509790YA (en)	2010-11-30	2015-12-30	Chugai Pharmaceutical Co Ltd	Antigen-Binding Molecule Capable Of Binding To Plurality Of Antigen Molecules Repeatedly
EP2655413B1 (en)	2010-12-23	2019-01-16	F.Hoffmann-La Roche Ag	Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
US10689447B2 (en)	2011-02-04	2020-06-23	Genentech, Inc.	Fc variants and methods for their production
SG10201609665PA (en)	2011-02-25	2017-01-27	Chugai Pharmaceutical Co Ltd	FcɣRIIb-SPECIFIC Fc ANTIBODY
ES2549638T3 (es)	2011-02-28	2015-10-30	F. Hoffmann-La Roche Ag	Proteínas de unión a antígeno
CN103403025B (zh)	2011-02-28	2016-10-12	弗·哈夫曼-拉罗切有限公司	单价抗原结合蛋白
HUE041335T2 (hu)	2011-03-29	2019-05-28	Roche Glycart Ag	Antitest FC-variánsok
RU2641256C2 (ru)	2011-06-30	2018-01-16	Чугаи Сейяку Кабусики Кайся	Гетеродимеризованный полипептид
UA117901C2 (uk)	2011-07-06	2018-10-25	Ґенмаб Б.В.	Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
IL282122B2 (en) *	2011-07-06	2025-10-01	Genmab Bv	Antibody variants and their uses
US20140335089A1 (en)	2011-09-30	2014-11-13	Chugai Seiyaku Kabushiki Kaisha	Antigen-binding molecule for promoting elimination of antigens
TW201817745A (zh)	2011-09-30	2018-05-16	日商中外製藥股份有限公司	具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
JP6322411B2 (ja)	2011-09-30	2018-05-09	中外製薬株式会社	複数の生理活性を有する抗原の消失を促進する抗原結合分子
SG11201401100UA (en)	2011-09-30	2014-07-30	Chugai Pharmaceutical Co Ltd	Antigen-binding molecule inducing immune response to target antigen
US20150299313A1 (en)	2011-10-05	2015-10-22	Chugai Seiyaku Kabushiki Kaisha	Antigen-binding molecule for promoting clearance from plasma of antigen comprising suger chain receptor-binding domain
JP6140712B2 (ja)	2011-10-11	2017-05-31	メディミューン，エルエルシー	ＣＤ４０Ｌ特異的Ｔｎ３由来足場およびその使用方法
CN113416257A (zh)	2011-11-30	2021-09-21	中外制药株式会社	包含进入细胞内以形成免疫复合体的搬运体(载体)的药物
KR102041412B1 (ko) *	2011-12-30	2019-11-11	한미사이언스 주식회사	면역글로불린 Ｆｃ 단편 유도체
CN104204204A (zh)	2012-02-09	2014-12-10	中外制药株式会社	抗体的Fc区变异体
CN104105711B (zh)	2012-02-10	2018-11-30	弗·哈夫曼-拉罗切有限公司	单链抗体及其他异多聚体
ES2676031T3 (es)	2012-02-15	2018-07-16	F. Hoffmann-La Roche Ag	Cromatografía de afinidad basada en el receptor Fc
KR102219987B1 (ko)	2012-02-24	2021-02-25	추가이 세이야쿠 가부시키가이샤	ＦｃγＲＩＩＢ를 매개로 항원의 소실을 촉진하는 항원 결합 분자
CN104487457B (zh)	2012-05-30	2018-01-26	中外制药株式会社	靶组织特异性抗原结合分子
EP2857419B1 (en)	2012-05-30	2021-01-13	Chugai Seiyaku Kabushiki Kaisha	Antigen-binding molecule for eliminating aggregated antigens
HK1207864A1 (zh)	2012-06-27	2016-02-12	F. Hoffmann-La Roche Ag	用於选择并产生含有至少两种不同结合实体的定制高度选择性和多特异性靶向实体的方法及其用途
MX2014014804A (es)	2012-06-27	2015-02-12	Hoffmann La Roche	Metodo para la elaboracion de conjugados de la region fc de anticuerpos que comprenden por lo menos una entidad de union que se une especificamente a un objetivo y usos del mismo.
SG10201605703TA (en)	2012-07-06	2016-09-29	Genmab Bv	Dimeric protein with triple mutations
EP3632462A1 (en) *	2012-07-06	2020-04-08	Genmab B.V.	Dimeric protein with triple mutations
WO2014009465A1 (en)	2012-07-13	2014-01-16	Roche Glycart Ag	Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
TWI717591B (zh)	2012-08-24	2021-02-01	日商中外製藥股份有限公司	ＦｃγＲＩＩｂ特異性Ｆｃ區域變異體
US11236168B2 (en)	2012-08-24	2022-02-01	Chugai Seiyaku Kabushiki Kaisha	Mouse FcγammaRII-specific Fc antibody
JP6433297B2 (ja)	2012-12-27	2018-12-05	中外製薬株式会社	ヘテロ二量化ポリペプチド
US20150353636A1 (en) *	2013-01-10	2015-12-10	Genmab B.V.	Human igg1 fc region variants and uses thereof
PT3611180T (pt) *	2013-03-15	2022-03-15	Biomolecular Holdings Llc	Imunoglobulina híbrida que contém uma ligação não peptídica
TWI636062B (zh)	2013-04-02	2018-09-21	中外製藥股份有限公司	Fc region variant
US20160068613A1 (en) *	2013-04-29	2016-03-10	Hoffmann-La Roche Inc.	Fc-receptor binding modified asymmetric antibodies and methods of use
SG11201508911PA (en)	2013-04-29	2015-11-27	Hoffmann La Roche	Human fcrn-binding modified antibodies and methods of use
KR20160044060A (ko)	2013-10-11	2016-04-22	에프. 호프만-라 로슈 아게	다중특이적 도메인 교환된 통상의 가변 경쇄 항체
BR112016014969A2 (pt)	2014-01-15	2018-01-23	Hoffmann La Roche	polipeptídeo, formulação farmacêutica e uso de um polipeptídeo
NZ631007A (en)	2014-03-07	2015-10-30	Alexion Pharma Inc	Anti-c5 antibodies having improved pharmacokinetics
NZ724904A (en)	2014-03-14	2023-04-28	Biomolecular Holdings Llc	Hybrid immunoglobulin containing non-peptidyl linkage
JP6744855B2 (ja)	2014-03-21	2020-08-19	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	抗体のｉｎｖｉｖｏでの半減期のｉｎｖｉｔｒｏでの予測
BR112016024462B1 (pt)	2014-05-06	2022-12-27	Genentech, Inc	Métodos para a preparação de um anticorpo
US9840553B2 (en)	2014-06-28	2017-12-12	Kodiak Sciences Inc.	Dual PDGF/VEGF antagonists
DK3215528T3 (da) *	2014-11-06	2019-10-07	Hoffmann La Roche	Fc-regionvarianter med modificeret FcRn-binding og anvendelsesfremgangsmåder
ES2764111T3 (es)	2014-12-03	2020-06-02	Hoffmann La Roche	Anticuerpos multiespecíficos
KR102650420B1 (ko)	2014-12-19	2024-03-21	추가이 세이야쿠 가부시키가이샤	항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
CN112142844B (zh)	2015-02-05	2025-07-25	中外制药株式会社	包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il-8-结合抗体及其应用
FR3034420A1 (fr)	2015-03-31	2016-10-07	Lab Francais Du Fractionnement	Anticorps monoclonaux anti-cd303
CA3002422C (en)	2015-12-18	2024-04-16	Chugai Seiyaku Kabushiki Kaisha	Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
US11359009B2 (en)	2015-12-25	2022-06-14	Chugai Seiyaku Kabushiki Kaisha	Anti-myostatin antibodies and methods of use
SG11201805420SA (en)	2015-12-30	2018-07-30	Kodiak Sciences Inc	Antibodies and conjugates thereof
HRP20260060T1 (hr) *	2016-03-14	2026-03-27	Universitetet I Oslo	Genetskim inženjeringom dobiveni imunoglobulini s izmijenjenim vezivanjem za fcrn
CN108778333A (zh) *	2016-03-14	2018-11-09	生物测试股份公司	严重社区获得性肺炎的治疗
BR112018073945A2 (pt)	2016-05-27	2019-02-26	Alexion Pharmaceuticals, Inc.	métodos para tratamento de miastenia grave generalizada refratária
KR102680483B1 (ko)	2016-06-17	2024-07-01	추가이 세이야쿠 가부시키가이샤	항-마이오스타틴 항체 및 사용 방법
KR20190039937A (ko)	2016-07-08	2019-04-16	스태튼 바이오테크놀로지 비.브이.	항-ApoC3 항체 및 이의 사용 방법
CA3032820A1 (en) *	2016-08-02	2018-03-22	Visterra, Inc.	Engineered polypeptides and uses thereof
MX2019001448A (es)	2016-08-05	2019-09-13	Chugai Pharmaceutical Co Ltd	Composicion para profilaxis o tratamiento de enfermedades relacionadas con interleucina 8 (il-8).
SG10201607778XA (en)	2016-09-16	2018-04-27	Chugai Pharmaceutical Co Ltd	Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
WO2018129714A1 (zh) *	2017-01-13	2018-07-19	杭州翰思生物医药有限公司	抗pd-1的单克隆抗体及其应用
CA3059133A1 (en)	2017-04-21	2018-10-25	Staten Biotechnology B.V.	Anti-apoc3 antibodies and methods of use thereof
EP3620531A4 (en)	2017-05-02	2021-03-17	National Center of Neurology and Psychiatry	METHOD OF PREDICTION AND EVALUATION OF THERAPEUTIC EFFECT IN DISEASES RELATING TO IL-6 AND NEUTROPHILS
CN107748259A (zh) *	2017-07-26	2018-03-02	东曜药业有限公司	一种FcRn受体的ELISA检测方法
SI3658184T1 (sl)	2017-07-27	2024-01-31	Alexion Pharmaceuticals, Inc.,	Formulacije z visoko koncentracijo protiteles proti-C5
WO2019084438A1 (en)	2017-10-26	2019-05-02	Alexion Pharmaceuticals, Inc.	ASSAY AND ADMINISTRATION OF ANTI-C5 ANTIBODIES FOR THE TREATMENT OF NOCTURNAL PAROXYSTIC HEMOGLOBINURIA (PNH) AND ATYPICAL HEMOLYTIC AND UREMIC SYNDROME (AHUS)
US10538583B2 (en)	2017-10-31	2020-01-21	Staten Biotechnology B.V.	Anti-APOC3 antibodies and compositions thereof
KR20200074975A (ko)	2017-10-31	2020-06-25	스태튼 바이오테크놀로지 비.브이.	항-ApoC3 항체 및 이의 사용 방법
EP3710589A4 (en)	2017-11-14	2021-11-10	Chugai Seiyaku Kabushiki Kaisha	ANTI-C1S ANTIBODIES AND METHOD OF USING
EP3498293A1 (en)	2017-12-15	2019-06-19	Institut National De La Sante Et De La Recherche Medicale (Inserm)	Treatment of monogenic diseases with an anti-cd45rc antibody
FR3076294B1 (fr)	2017-12-29	2022-01-28	Lab Francais Du Fractionnement	Procede de purification d'anticorps a partir de lait brut
CN108101992B (zh) *	2017-12-31	2021-03-26	武汉班科生物技术股份有限公司	与新生的Fc受体结合增强的CH2结构域突变体及其制备方法与应用
JP2018138022A (ja) *	2018-02-23	2018-09-06	ゲンマブビー．ブイ．	ヒトＩｇＧ１Ｆｃ領域変異体およびその使用
CA3092588A1 (en)	2018-03-02	2019-09-06	Kodiak Sciences Inc.	Il-6 antibodies and fusion constructs and conjugates thereof
US20200040103A1 (en)	2018-03-14	2020-02-06	Genentech, Inc.	Anti-klk5 antibodies and methods of use
CN116327926A (zh)	2018-03-15	2023-06-27	中外制药株式会社	对寨卡病毒具有交叉反应性的抗登革热病毒抗体及使用方法
CN108519383B (zh) *	2018-04-08	2020-08-14	上海理工大学	一种全波段生物显色实验的检测方法
WO2019231983A1 (en)	2018-05-31	2019-12-05	Alexion Pharmaceuticals, Inc.	Dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) in pediatric patients
EP3802603A1 (en)	2018-06-04	2021-04-14	Alexion Pharmaceuticals, Inc.	Dosage and administration of anti-c5 antibodies for treatment of atypical hemolytic uremic syndrome (ahus) in pediatric patients
US20210238308A1 (en) *	2018-06-04	2021-08-05	Chugai Seiyaku Kabushiki Kaisha	Antigen-binding molecule showing changed half-life in cytoplasm
WO2019246404A1 (en) *	2018-06-22	2019-12-26	Cugene Inc.	Interleukin-2 variants and methods of uses thereof
US12312394B2 (en)	2018-06-28	2025-05-27	Alexion Pharmaceuticals, Inc.	Methods of producing anti-C5 antibodies
PE20210343A1 (es)	2018-08-10	2021-02-23	Chugai Pharmaceutical Co Ltd	Molecula de union al antigeno anti grupo de diferenciacion 137 (cd137) y su uso
MA54052A (fr)	2018-10-29	2022-02-09	Hoffmann La Roche	Formulation d'anticorps
JP2022512632A (ja)	2018-10-30	2022-02-07	アレクシオンファーマシューティカルズ，インコーポレイテッド	発作性夜間ヘモグロビン尿症（ｐｎｈ）の処置のための抗ｃ５抗体の皮下投薬及び投与
US20220089765A1 (en)	2019-01-23	2022-03-24	Encefa	Cd31 competitors and uses thereof
AU2020275348A1 (en)	2019-05-15	2021-12-09	Chugai Seiyaku Kabushiki Kaisha	An antigen-binding molecule, a pharmaceutical composition, and a method
US12312414B2 (en)	2019-09-18	2025-05-27	Genentech, Inc.	Anti-KLK7 antibodies, anti-KLK5 antibodies, multispecific anti-KLK5/KLK7 antibodies, and methods of use
CA3155187A1 (en) *	2019-09-18	2021-03-25	Momenta Pharmaceuticals, Inc.	Compositions and methods related to engineered fc-antigen binding domain constructs targeted to cd38
AU2020364071A1 (en)	2019-10-10	2022-05-26	Kodiak Sciences Inc.	Methods of treating an eye disorder
MX2022007479A (es)	2019-12-18	2022-06-29	Hoffmann La Roche	Anticuerpos anti-ccl2 biespecificos.
CN113637084B (zh) *	2020-05-11	2025-08-01	上海康景生物医药科技有限公司	生物大分子靶向特异性补体抑制剂及其制备方法与应用
KR20240021859A (ko)	2021-06-18	2024-02-19	에프. 호프만-라 로슈 아게	이중특이적 항-ccl2 항체
CA3265515A1 (en) *	2022-09-02	2024-03-07	Zoetis Services Llc	EQUINE ANTIBODY MUTANTS
CN121319170A (zh) *	2024-07-12	2026-01-13	菲鹏生物股份有限公司	免疫球蛋白及其用途
WO2026039779A1 (en)	2024-08-15	2026-02-19	Yale University	Humanized 3e10 antibodies and antigen binding fragments optimized for rad51 binding

Family Cites Families (141)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3773919A (en)	1969-10-23	1973-11-20	Du Pont	Polylactide-drug mixtures
CU22545A1 (es)	1994-11-18	1999-03-31	Centro Inmunologia Molecular	Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
FR2413974A1 (fr)	1978-01-06	1979-08-03	David Bernard	Sechoir pour feuilles imprimees par serigraphie
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4675187A (en)	1983-05-16	1987-06-23	Bristol-Myers Company	BBM-1675, a new antibiotic complex
US4943533A (en)	1984-03-01	1990-07-24	The Regents Of The University Of California	Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
US4676980A (en)	1985-09-23	1987-06-30	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Target specific cross-linked heteroantibodies
US6548640B1 (en)	1986-03-27	2003-04-15	Btg International Limited	Altered antibodies
IL85035A0 (en)	1987-01-08	1988-06-30	Int Genetic Eng	Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5004697A (en)	1987-08-17	1991-04-02	Univ. Of Ca	Cationized antibodies for delivery through the blood-brain barrier
JP3040121B2 (ja)	1988-01-12	2000-05-08	ジェネンテク，インコーポレイテッド	増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
GB8823869D0 (en)	1988-10-12	1988-11-16	Medical Res Council	Production of antibodies
US5047335A (en) *	1988-12-21	1991-09-10	The Regents Of The University Of Calif.	Process for controlling intracellular glycosylation of proteins
DE3920358A1 (de)	1989-06-22	1991-01-17	Behringwerke Ag	Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
AU641673B2 (en)	1989-06-29	1993-09-30	Medarex, Inc.	Bispecific reagents for aids therapy
JP3068180B2 (ja)	1990-01-12	2000-07-24	アブジェニックスインコーポレイテッド	異種抗体の生成
US6150584A (en)	1990-01-12	2000-11-21	Abgenix, Inc.	Human antibodies derived from immunized xenomice
US6075181A (en)	1990-01-12	2000-06-13	Abgenix, Inc.	Human antibodies derived from immunized xenomice
US5112596A (en)	1990-04-23	1992-05-12	Alkermes, Inc.	Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability
US5268164A (en)	1990-04-23	1993-12-07	Alkermes, Inc.	Increasing blood-brain barrier permeability with permeabilizer peptides
DE69132709T2 (de)	1990-06-29	2002-06-20	Large Scale Biology Corp., Vacaville	Melaninproduktion durch transformierte mikroorganismen
DE69133476T2 (de)	1990-08-29	2006-01-05	GenPharm International, Inc., Palo Alto	Transgene Mäuse fähig zur Produktion heterologer Antikörper
US5545806A (en)	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en)	1990-08-29	1997-08-26	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en)	1990-08-29	1997-04-29	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
US5633425A (en)	1990-08-29	1997-05-27	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
WO1992015683A1 (en)	1991-03-06	1992-09-17	MERCK Patent Gesellschaft mit beschränkter Haftung	Humanized and chimeric monoclonal antibodies
US5278299A (en) *	1991-03-18	1994-01-11	Scripps Clinic And Research Foundation	Method and composition for synthesizing sialylated glycosyl compounds
US6582959B2 (en)	1991-03-29	2003-06-24	Genentech, Inc.	Antibodies to vascular endothelial cell growth factor
US20030206899A1 (en)	1991-03-29	2003-11-06	Genentech, Inc.	Vascular endothelial cell growth factor antagonists
ES2206447T3 (es)	1991-06-14	2004-05-16	Genentech, Inc.	Anticuerpo humanizado para heregulina.
WO1994004679A1 (en)	1991-06-14	1994-03-03	Genentech, Inc.	Method for making humanized antibodies
GB9114948D0 (en)	1991-07-11	1991-08-28	Pfizer Ltd	Process for preparing sertraline intermediates
WO1993006213A1 (en)	1991-09-23	1993-04-01	Medical Research Council	Production of chimeric antibodies - a combinatorial approach
WO1993008829A1 (en)	1991-11-04	1993-05-13	The Regents Of The University Of California	Compositions that mediate killing of hiv-infected cells
AU3144193A (en) *	1991-11-21	1993-06-15	Board Of Trustees Of The Leland Stanford Junior University	Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases
DE69328430T2 (de)	1992-07-27	2001-01-25	The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer	Zielgerichte liposome zur blut-hirne schranke
WO1994004690A1 (en)	1992-08-17	1994-03-03	Genentech, Inc.	Bispecific immunoadhesins
CZ291047B6 (cs)	1992-10-28	2002-12-11	Genentech, Inc.	Farmaceutický prostředek obsahující antagonisty faktoru růstu vaskulárních endoteliálních buněk
GB9401182D0 (en)	1994-01-21	1994-03-16	Inst Of Cancer The Research	Antibodies to EGF receptor and their antitumour effect
US5635388A (en)	1994-04-04	1997-06-03	Genentech, Inc.	Agonist antibodies against the flk2/flt3 receptor and uses thereof
US5731168A (en)	1995-03-01	1998-03-24	Genentech, Inc.	Method for making heteromultimeric polypeptides
IL117645A (en)	1995-03-30	2005-08-31	Genentech Inc	Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
US5641870A (en)	1995-04-20	1997-06-24	Genentech, Inc.	Low pH hydrophobic interaction chromatography for antibody purification
US6096871A (en)	1995-04-14	2000-08-01	Genentech, Inc.	Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5869046A (en)	1995-04-14	1999-02-09	Genentech, Inc.	Altered polypeptides with increased half-life
US5747035A (en)	1995-04-14	1998-05-05	Genentech, Inc.	Polypeptides with increased half-life for use in treating disorders involving the LFA-1 receptor
DE69637481T2 (de)	1995-04-27	2009-04-09	Amgen Fremont Inc.	Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8
AU2466895A (en)	1995-04-28	1996-11-18	Abgenix, Inc.	Human antibodies derived from immunized xenomice
JPH11507535A (ja)	1995-06-07	1999-07-06	イムクローンシステムズインコーポレイテッド	腫瘍の成長を抑制する抗体および抗体フラグメント類
GB9603256D0 (en)	1996-02-16	1996-04-17	Wellcome Found	Antibodies
JP4046354B2 (ja) *	1996-03-18	2008-02-13	ボードオブリージェンツ，ザユニバーシティオブテキサスシステム	増大した半減期を有する免疫グロブリン様ドメイン
WO1997043316A1 (en)	1996-05-10	1997-11-20	Beth Israel Deaconess Medical Center, Inc.	Physiologically active molecules with extended half-lives and methods of using same
JP4215172B2 (ja)	1996-12-03	2009-01-28	アムジェンフレモントインク．	複数のＶ▲下Ｈ▼およびＶ▲下κ▼領域を含むヒトＩｇ遺伝子座を有するトランスジェニック哺乳動物、ならびにそれから産生される抗体
WO1998045331A2 (en)	1997-04-07	1998-10-15	Genentech, Inc.	Anti-vegf antibodies
US20020032315A1 (en)	1997-08-06	2002-03-14	Manuel Baca	Anti-vegf antibodies
KR100856995B1 (ko)	1997-04-07	2008-09-04	제넨테크, 인크.	인간화 항체 및 인간화 항체의 제조 방법
US6884879B1 (en)	1997-04-07	2005-04-26	Genentech, Inc.	Anti-VEGF antibodies
EP0915987A2 (en)	1997-04-21	1999-05-19	Donlar Corporation	POLY-($g(a)-L-ASPARTIC ACID), POLY-($g(a)-L-GLUTAMIC ACID) AND COPOLYMERS OF L-ASP AND L-GLU, METHOD FOR THEIR PRODUCTION AND THEIR USE
US6235883B1 (en)	1997-05-05	2001-05-22	Abgenix, Inc.	Human monoclonal antibodies to epidermal growth factor receptor
CA2293829C (en)	1997-06-24	2011-06-14	Genentech, Inc.	Methods and compositions for galactosylated glycoproteins
US20040191256A1 (en) *	1997-06-24	2004-09-30	Genentech, Inc.	Methods and compositions for galactosylated glycoproteins
US6172213B1 (en) *	1997-07-02	2001-01-09	Genentech, Inc.	Anti-IgE antibodies and method of improving polypeptides
DE69840412D1 (de)	1997-10-31	2009-02-12	Genentech Inc	Methoden und zusammensetzungen bestehend aus glykoprotein-glykoformen
ATE531812T1 (de)	1997-12-05	2011-11-15	Scripps Research Inst	Humanisierung von nager-antikörpern
US6194551B1 (en) *	1998-04-02	2001-02-27	Genentech, Inc.	Polypeptide variants
US6528624B1 (en) *	1998-04-02	2003-03-04	Genentech, Inc.	Polypeptide variants
CA2323757C (en)	1998-04-02	2011-08-02	Genentech, Inc.	Antibody variants and fragments thereof
EP1071700B1 (en) *	1998-04-20	2010-02-17	GlycArt Biotechnology AG	Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
CN1260249C (zh)	1998-05-06	2006-06-21	基因技术股份有限公司	用离子交换层析纯化蛋白质
US6737056B1 (en) *	1999-01-15	2004-05-18	Genentech, Inc.	Polypeptide variants with altered effector function
US7183387B1 (en) *	1999-01-15	2007-02-27	Genentech, Inc.	Polypeptide variants with altered effector function
HUP0104865A3 (en) *	1999-01-15	2004-07-28	Genentech Inc	Polypeptide variants with altered effector function
EP2264166B1 (en)	1999-04-09	2016-03-23	Kyowa Hakko Kirin Co., Ltd.	Method for controlling the activity of immunologically functional molecule
US6703020B1 (en)	1999-04-28	2004-03-09	Board Of Regents, The University Of Texas System	Antibody conjugate methods for selectively inhibiting VEGF
WO2001029246A1 (fr)	1999-10-19	2001-04-26	Kyowa Hakko Kogyo Co., Ltd.	Procede de production d'un polypeptide
ATE419354T1 (de)	2000-02-25	2009-01-15	Us Gov Health & Human Serv	Scfv-moleküle gegen egfrviii mit verbesserter zytotoxizität und ausbeute, darauf basierte immuntoxine, und verfahren zur deren verwendung
US7449443B2 (en)	2000-03-23	2008-11-11	California Institute Of Technology	Method for stabilization of proteins using non-natural amino acids
JP2003531149A (ja) *	2000-04-13	2003-10-21	ザ・ロツクフエラー・ユニバーシテイ	抗体由来の免疫応答の増強
CA2409361A1 (en)	2000-05-19	2001-11-22	Scancell Limited	Humanised antibodies to the epidermal growth factor receptor
US6586207B2 (en)	2000-05-26	2003-07-01	California Institute Of Technology	Overexpression of aminoacyl-tRNA synthetases for efficient production of engineered proteins containing amino acid analogues
EP1292335B1 (en)	2000-06-23	2007-05-30	Bayer Schering Pharma Aktiengesellschaft	Combinations and compositions which interfere with vegf/vegf and angiopoietin/tie receptor function and their use (ii)
US7598055B2 (en) *	2000-06-28	2009-10-06	Glycofi, Inc.	N-acetylglucosaminyltransferase III expression in lower eukaryotes
US6514221B2 (en)	2000-07-27	2003-02-04	Brigham And Women's Hospital, Inc.	Blood-brain barrier opening
AU2001286930A1 (en)	2000-08-30	2002-03-13	The Board Of Trustees Of The Leland Stanford Junior University	Glucocorticoid blocking agents for increasing blood-brain barrier permeability
US6946292B2 (en) *	2000-10-06	2005-09-20	Kyowa Hakko Kogyo Co., Ltd.	Cells producing antibody compositions with increased antibody dependent cytotoxic activity
HU231090B1 (hu)	2000-10-06	2020-07-28	Kyowa Kirin Co., Ltd.	Antitest-kompozíciót termelő sejt
US7064191B2 (en)	2000-10-06	2006-06-20	Kyowa Hakko Kogyo Co., Ltd.	Process for purifying antibody
US7034036B2 (en)	2000-10-30	2006-04-25	Pain Therapeutics, Inc.	Inhibitors of ABC drug transporters at the blood-brain barrier
US20030083299A1 (en)	2000-11-04	2003-05-01	Ferguson Ian A.	Non-invasive delivery of polypeptides through the blood-brain barrier
US6480405B2 (en) *	2000-11-17	2002-11-12	Texas Instruments Incorporated	Full-wave rectifier
AU2002248184C1 (en) *	2000-12-12	2018-01-04	Board Of Regents, The University Of Texas System	Molecules with extended half-lives, compositions and uses thereof
RU2420537C2 (ru) *	2001-01-17	2011-06-10	Трабьон Фармасьютикалз Инк.	Слитые белки связывающий домен-иммуноглобулин
WO2002078766A2 (en) *	2001-04-02	2002-10-10	Genentech, Inc.	Combination therapy
DE10121982B4 (de)	2001-05-05	2008-01-24	Lts Lohmann Therapie-Systeme Ag	Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung
EP1395284B1 (en)	2001-06-14	2010-12-08	Isis Innovation Limited	Non-depleting anti-CD4 antibody TRX1 and its uses
WO2003009815A2 (en)	2001-07-25	2003-02-06	Biomarin Pharmaceutical Inc.	Compositions and methods for modulating blood-brain barrier transport
NZ581474A (en)	2001-08-03	2011-04-29	Glycart Biotechnology Ag	Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
CA2463879C (en) *	2001-10-25	2012-12-04	Genentech, Inc.	Glycoprotein compositions
US20040093621A1 (en) *	2001-12-25	2004-05-13	Kyowa Hakko Kogyo Co., Ltd	Antibody composition which specifically binds to CD20
EP1490677A4 (en)	2002-02-27	2006-01-18	California Inst Of Techn	COMPUTER METHOD FOR DESIGNING ENZYMES FOR THE INCORPORATION OF AMINO ACID ANALOGUES INTO PROTEINS
US20030162695A1 (en)	2002-02-27	2003-08-28	Schatzberg Alan F.	Glucocorticoid blocking agents for increasing blood-brain barrier permeability
US20050031613A1 (en)	2002-04-09	2005-02-10	Kazuyasu Nakamura	Therapeutic agent for patients having human FcgammaRIIIa
AU2003236018A1 (en)	2002-04-09	2003-10-20	Kyowa Hakko Kirin Co., Ltd.	METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcGamma RECEPTOR IIIa
AU2003236015A1 (en)	2002-04-09	2003-10-20	Kyowa Hakko Kirin Co., Ltd.	Process for producing antibody composition
AU2003236017B2 (en)	2002-04-09	2009-03-26	Kyowa Kirin Co., Ltd.	Drug containing antibody composition
DE60336548D1 (de)	2002-04-09	2011-05-12	Kyowa Hakko Kirin Co Ltd	Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins
WO2003085107A1 (en)	2002-04-09	2003-10-16	Kyowa Hakko Kogyo Co., Ltd.	Cells with modified genome
SE0302312D0 (sv)	2002-10-04	2003-08-27	Forskarpatent I Syd Ab	Peptide-based passive immunization therapy for treatment of atherosclerosis
AU2003267905B2 (en)	2002-10-04	2009-02-05	Biolnvent International Ab	Peptide-based passive immunization therapy for treatment of atherosclerosis
US7217797B2 (en)	2002-10-15	2007-05-15	Pdl Biopharma, Inc.	Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
CA2507762C (en)	2002-12-03	2013-02-05	Blanchette Rockefeller Neurosciences Institute	Artificial low-density lipoprotein carriers for transport of substances across the blood-brain barrier
CN103833854B (zh)	2002-12-16	2017-12-12	健泰科生物技术公司	免疫球蛋白变体及其用途
EP2368578A1 (en) *	2003-01-09	2011-09-28	Macrogenics, Inc.	Identification and engineering of antibodies with variant Fc regions and methods of using same
ATE469888T1 (de)	2003-05-22	2010-06-15	Abbott Lab	Indazol-, benzisoxazol- und benzisothiazol- kinaseinhibitoren
RS20150135A1 (sr) *	2003-05-30	2015-08-31	Genentech Inc.	Tretman sa anti-vegf antitelima
US20050106667A1 (en)	2003-08-01	2005-05-19	Genentech, Inc	Binding polypeptides with restricted diversity sequences
US7758859B2 (en)	2003-08-01	2010-07-20	Genentech, Inc.	Anti-VEGF antibodies
WO2005044853A2 (en)	2003-11-01	2005-05-19	Genentech, Inc.	Anti-vegf antibodies
JP2007505142A (ja)	2003-09-10	2007-03-08	セダーズ−シナイメディカルセンター	血液脳関門を通過する薬剤のカリウムチャネル媒介性送達
US20080241884A1 (en)	2003-10-08	2008-10-02	Kenya Shitara	Fused Protein Composition
AU2004280065A1 (en)	2003-10-09	2005-04-21	Kyowa Hakko Kirin Co., Ltd.	Process for producing antibody composition by using RNA inhibiting the function of alpha1,6-fucosyltransferase
ES2737837T3 (es)	2003-10-09	2020-01-16	Ambrx Inc	Derivados poliméricos
LT2077282T (lt)	2003-11-05	2017-03-10	Roche Glycart Ag	Antigeną surišančios molekulės su padidintu fc receptoriaus surišimo giminingumu ir efektoriaus funkcija
JPWO2005053742A1 (ja)	2003-12-04	2007-06-28	協和醗酵工業株式会社	抗体組成物を含有する医薬
US7118999B2 (en) *	2004-01-16	2006-10-10	International Business Machines Corporation	Method and apparatus to increase strain effect in a transistor channel
NZ548256A (en)	2004-02-02	2010-02-26	Ambrx Inc	Modified human four helical bundle polypeptides and their uses
US20060009360A1 (en)	2004-06-25	2006-01-12	Robert Pifer	New adjuvant composition
MX2007000404A (es) *	2004-07-12	2008-03-04	Macrogenics Inc	Identificacion de ingenieria de anticuerpos con regiones de fc variante y metodos para usar las mismas.
PL2213683T3 (pl) *	2004-08-04	2013-10-31	Mentrik Biotech Llc	WARIANTY REGIONÓW Fc
EP1778728A2 (en) *	2004-08-19	2007-05-02	Genentech, Inc.	Polypeptide variants with altered effector function
US8367805B2 (en) *	2004-11-12	2013-02-05	Xencor, Inc.	Fc variants with altered binding to FcRn
EP2332985A3 (en) *	2004-11-12	2012-01-25	Xencor, Inc.	Fc variants with altered binding to FcRn
US8802820B2 (en) *	2004-11-12	2014-08-12	Xencor, Inc.	Fc variants with altered binding to FcRn
RU2412200C2 (ru) *	2004-11-12	2011-02-20	Ксенкор, Инк.	Fc-ВАРИАНТЫ С ИЗМЕНЕННЫМ СВЯЗЫВАНИЕМ С FcRn
JP2008526205A (ja)	2004-12-31	2008-07-24	ジェネンテック・インコーポレーテッド	Ｂｒ３に結合するポリペプチド及びその使用
DE602005026067D1 (de) *	2005-09-07	2011-03-03	Palcan Y Bin S L	Dreidimensionales puzzle
AU2007227609A1 (en) *	2006-03-16	2007-09-27	Genentech, Inc.	Methods of treating lupus using CD4 antibodies
WO2008140603A2 (en) *	2006-12-08	2008-11-20	Macrogenics, Inc.	METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING
TWI468417B (zh)	2007-11-30	2015-01-11	Genentech Inc	抗－ｖｅｇｆ抗體
DK2235059T3 (en) *	2007-12-26	2015-03-30	Xencor Inc	FC-VERSIONS OF MODIFIED BINDING TO FcRn

2009
- 2009-10-13 KR KR1020117010964A patent/KR101834999B1/ko not_active Expired - Fee Related
- 2009-10-13 AU AU2009303526A patent/AU2009303526B2/en not_active Ceased
- 2009-10-13 PL PL09793631T patent/PL2352521T3/pl unknown
- 2009-10-13 MX MX2011004001A patent/MX2011004001A/es active IP Right Grant
- 2009-10-13 PE PE2011000886A patent/PE20110707A1/es active IP Right Grant
- 2009-10-13 EP EP18212252.3A patent/EP3524620A1/en not_active Withdrawn
- 2009-10-13 JP JP2011531249A patent/JP5913980B2/ja not_active Expired - Fee Related
- 2009-10-13 CA CA2739429A patent/CA2739429C/en active Active
- 2009-10-13 EP EP09793631.4A patent/EP2352521B1/en active Active
- 2009-10-13 RU RU2011119447/10A patent/RU2536937C2/ru active
- 2009-10-13 KR KR1020197005957A patent/KR20190025057A/ko not_active Withdrawn
- 2009-10-13 TW TW104123461A patent/TWI572359B/zh not_active IP Right Cessation
- 2009-10-13 AR ARP090103925A patent/AR073829A1/es not_active Application Discontinuation
- 2009-10-13 SG SG10201605250SA patent/SG10201605250SA/en unknown
- 2009-10-13 PE PE2015000431A patent/PE20150682A1/es active IP Right Grant
- 2009-10-13 WO PCT/US2009/060443 patent/WO2010045193A1/en not_active Ceased
- 2009-10-13 CN CN200980150204.0A patent/CN102245208B/zh not_active Expired - Fee Related
- 2009-10-13 BR BRPI0914091-3A patent/BRPI0914091B1/pt not_active IP Right Cessation
- 2009-10-13 CN CN201410562388.4A patent/CN104447990B/zh not_active Expired - Fee Related
- 2009-10-13 TW TW098134687A patent/TWI572357B/zh not_active IP Right Cessation
- 2009-10-13 SG SG2013076815A patent/SG195558A1/en unknown
- 2009-10-13 ES ES09793631T patent/ES2828721T3/es active Active
- 2009-10-13 KR KR1020187005799A patent/KR102100066B1/ko not_active Expired - Fee Related
- 2009-10-13 CN CN201910548858.4A patent/CN110317272A/zh active Pending
- 2009-10-13 US US12/577,967 patent/US20100098730A1/en not_active Abandoned
2011
- 2011-03-31 IL IL212048A patent/IL212048B/en active IP Right Grant
- 2011-03-31 ZA ZA2011/02413A patent/ZA201102413B/en unknown
2014
- 2014-02-24 US US14/188,432 patent/US20140294810A1/en not_active Abandoned
2015
- 2015-01-21 CL CL2015000148A patent/CL2015000148A1/es unknown
- 2015-07-24 JP JP2015146850A patent/JP6122072B2/ja not_active Expired - Fee Related
2016
- 2016-01-12 PH PH12016500081A patent/PH12016500081B1/en unknown
2019
- 2019-01-08 IL IL264138A patent/IL264138A/en unknown
2020
- 2020-06-01 US US16/889,510 patent/US20210002359A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EP3524620A1 (en)	2019-08-14
ES2828721T3 (es)	2021-05-27
CN104447990A (zh)	2015-03-25
PL2352521T3 (pl)	2021-03-08
RU2536937C2 (ru)	2014-12-27
RU2011119447A (ru)	2012-11-27
BRPI0914091B1 (pt)	2022-05-10
US20100098730A1 (en)	2010-04-22
IL212048A0 (en)	2011-06-30
JP5913980B2 (ja)	2016-05-11
SG195558A1 (en)	2013-12-30
CN102245208B (zh)	2016-03-16
TWI572359B (zh)	2017-03-01
ZA201102413B (en)	2012-06-27
SG10201605250SA (en)	2016-08-30
CA2739429A1 (en)	2010-04-22
IL212048B (en)	2020-02-27
CA2739429C (en)	2020-12-22
JP2016026144A (ja)	2016-02-12
KR20190025057A (ko)	2019-03-08
JP6122072B2 (ja)	2017-04-26
US20210002359A1 (en)	2021-01-07
HK1209130A1 (en)	2016-03-24
AU2009303526B2 (en)	2015-01-15
WO2010045193A1 (en)	2010-04-22
KR102100066B1 (ko)	2020-04-10
HK1163550A1 (zh)	2012-09-14
AR073829A1 (es)	2010-12-01
PH12016500081A1 (en)	2017-01-16
TW201023884A (en)	2010-07-01
KR20180027609A (ko)	2018-03-14
EP2352521A1 (en)	2011-08-10
EP2352521B1 (en)	2020-09-16
IL264138A (en)	2019-02-28
JP2012505833A (ja)	2012-03-08
PH12016500081B1 (en)	2017-01-16
KR20110070914A (ko)	2011-06-24
CN104447990B (zh)	2019-07-19
KR101834999B1 (ko)	2018-03-06
CN102245208A (zh)	2011-11-16
PE20110707A1 (es)	2011-10-11
US20140294810A1 (en)	2014-10-02
CN110317272A (zh)	2019-10-11
AU2009303526A1 (en)	2010-04-22
PE20150682A1 (es)	2015-05-20
MX2011004001A (es)	2011-05-19
CL2015000148A1 (es)	2015-04-24
TWI572357B (zh)	2017-03-01
TW201542228A (zh)	2015-11-16

Legal Events

Date	Code	Title	Description
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2018-05-22	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2021-07-06	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
2021-08-17	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2021-11-23	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2022-03-15	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2022-05-10	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/10/2009, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.
2025-09-16	B21F	Lapse acc. art. 78, item iv - on non-payment of the annual fees in time	Free format text: REFERENTE A 16A ANUIDADE.
2026-01-06	B24J	Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)	Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2854 DE 16-09-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

Publication	Publication Date	Title
BRPI0914091A2 (pt)	2016-09-27	"igg variante, composição farmacêutica, kit, método para tratar em tumor, método para inibir atividade de vegf, método para modular permeabilidade vascular e método para inibir ou evitar crescimento de células de câncer"
BRPI0715845A2 (pt)	2014-11-11	Composição farmacêutica para tratamento do câncer de pulmão, método de inibição do crescimento ou invasão do câncer de pulmão e método de tratamento do câncer de pulmão
BRPI0813311A2 (pt)	2014-12-23	Composto, métodos para modulara a atividade de uma proteína quinase e para tratar câncer em um indivíduo, e, composição farmacêutica.
IL193746A (en)	2015-05-31	Antimicrobial compositions and catheters containing the same and methods for production thereof
BRPI0820568A2 (pt)	2015-06-16	Composto, composição farmacêutica, uso de um composto ou uma composição farmacêutica, e, método de tratamento de um humano ou animal
BR112012018947A8 (pt)	2017-12-19	composição farmacêutica para o tratamento e/ou prevenção de um câncer, anticorpo, combinação farmacêutica e método para o tratamento e/ou prevenção de um câncer
BRPI0812740A2 (pt)	2016-07-19	composto, composição farmacêutica, uso do composto, e, método para tratamento, prevenção ou alívio de um distúrbio do sistema nervoso central de um corpo de animal vivo.
WO2010034015A3 (en)	2010-07-22	Modulating the alternative complement pathway
DK1765391T3 (da)	2013-03-25	Bakterielle præparater til behandlingen af cancer
BRPI0714994A2 (pt)	2015-06-16	Sistema de tratamento de tecidos e método para controlar as informações sobre o tratamento de tecidos
BR112012018951A2 (pt)	2017-06-27	composição farmacêutica, combinação farmacêutica e método para o tratamento e\ou prevenção de um câncer e anticorpo
EP2046315A4 (en)	2009-09-16	THERAPEUTIC AGENTS FOR THE TREATMENT OF LYMPHOID MALIGNANCIES
BR112012018943A8 (pt)	2017-12-19	medicamento e método para o tratamento e/ou prevenção de um câncer
BRPI0908635A2 (pt)	2015-10-13	composto, composição farmacêutica e método de tratamento de câncer
CA2645871A1 (en)	2007-06-21	PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING OXALATE-ASSOCIATED DISEASE
BR112013011480A2 (pt)	2016-08-09	método de tratamento de câncer, método de aumento da eficácia terapêutica de uma droga anticâncer, pmo1183 ou um sal farmaceuticamente aceitável do mesmo, uso do mesmo e kit para uso no tratamento de câncer
ZA200707638B (en)	2009-08-26	Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer
BRPI1009860A2 (pt)	2016-03-08	composto, uso do mesmo, composição farmacêutica e método para tratamento terapêutico ou prevenção de doenças em humanos ou animais
WO2007146335A3 (en)	2009-02-12	Compounds and compositions for treatment of cancer
WO2007050784A3 (en)	2007-06-14	Fixed ratio drug combination treatments for solid tumors
BR112012002246A2 (pt)	2019-09-24	composto, composto ou sal farmaceutico aceitavel deste, composição farmaceutica, metodo para inibir, tratar e/ou reduzir o declinio cognitivol e/ou doença de akzhmer em um paciente
WO2010121164A3 (en)	2011-02-24	1,4-benzodiazepinone compounds and their use in treating cancer
BRPI0816952A2 (pt)	2015-03-24	Composição para tratar ou contralar uma infecção em um indivíduo, e, usos de uma fluoroquinolona e de uma combinação
BRPI0913854A2 (pt)	2016-05-17	composto, composição farmacêutica, uso do composto, e, método para o tratamento, a prevenção ou o alívio de uma doença ou um distúrbio ou uma condição de um organismo de animal vivente.
PL2234631T3 (pl)	2013-03-29	Związki i metody stosowane w terapii choroby naczyniowej